# Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

> **NCT02778919** · PHASE2 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.**

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** KLH-2109
- **DRUG:** Placebo
- **DRUG:** Leuprorelin acetate

## Key facts

- **NCT ID:** NCT02778919
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2018-03-23
- **Final completion:** 2018-03-23
- **Target enrollment:** — (—)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02778919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02778919, "Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02778919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*